2006 Compounding Drug Pricing 
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.
European Pharmaceutical Review
JANUARY 18, 2024
Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1
Expert insights. Personalized for you.
105 
Let's personalize your content